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Abstract
Background: All countries are facing decisions about which population groups to prioritize for access to COVID-19
vaccination after the first vaccine products have been licensed, at which time supply shortages are inevitable. Our
objective is to define the key target populations, their size, and priority for a COVID-19 vaccination program in the
context of China.
Methods: On the basis of utilitarian and egalitarian principles, we define and estimate the size of tiered target
population groups for a phased introduction of COVID-19 vaccination, considering evolving goals as vaccine
supplies increase, detailed information on the risk of illness and transmission, and past experience with vaccination
during the 2009 influenza pandemic. Using publicly available data, we estimated the size of target population
groups, and the number of days needed to vaccinate 70% of the target population. Sensitivity analyses considered
higher vaccine coverages and scaled up vaccine delivery relative to the 2009 pandemic.
Results: Essential workers, including staff in the healthcare, law enforcement, security, nursing homes, social welfare
institutes, community services, energy, food and transportation sectors, and overseas workers/students (49.7 million)
could be prioritized for vaccination to maintain essential services in the early phase of a vaccination program.
Subsequently, older adults, individuals with underlying health conditions and pregnant women (563.6 million) could
be targeted for vaccination to reduce the number of individuals with severe COVID-19 outcomes, including
hospitalizations, critical care admissions, and deaths. In later stages, the vaccination program could be further
extended to target adults without underlying health conditions and children (784.8 million), in order to reduce
symptomatic infections and/or to stop virus transmission. Given 10 million doses administered per day, and a two-
dose vaccination schedule, it would take 1 week to vaccinate essential workers but likely up to 7 months to
vaccinate 70% of the overall population.
Conclusions: The proposed framework is general but could assist Chinese policy-makers in the design of a vaccination
program. Additionally, this exercise could be generalized to inform other national and regional strategies for use of
COVID-19 vaccines, especially in low- and middle-income countries.
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Background
The pandemic is causing unprecedented impact on glo-
bal health and the economy. In the absence of safe and
highly effective vaccines and treatment options, non-
pharmaceutical interventions are used to decrease trans-
mission and reduce the burden of coronavirus disease
2019 (COVID-19) but most of these interventions have
large economic costs [1]. Effective vaccines against
COVID-19 are urgently needed to reduce the significant
burden of COVID-19 morbidity and mortality. Globally,
there are over 274 vaccine candidates at various stages
of development in the research pipeline. Of these, 59
candidates have entered clinical trials [2].
On June 26, 2020, the World Health Organization
(WHO) unveiled a plan to deliver 2 billion doses of
COVID-19 vaccines, of which 50% will go to low- and
middle-income countries, by the end of 2021 [3].
Currently, the projected global production capacity is in-
adequate to provide COVID-19 vaccines for every hu-
man being on the planet, particularly immediately after
the first vaccine has been licensed. It is possible that
countries and entire regions will have no access to vac-
cines. For example, COVID-19 cases are rapidly increas-
ing in most African countries [4]. However, none of the
COVID-19 vaccine candidates is being developed by an
African manufacturer. Even if a vaccine were available,
many low-income countries would have to rely on vac-
cines manufactured abroad. Hence national and multi-
national vaccine producers will need to allocate a
proportion of their production to countries that do not
have the financial ability to pre-order vaccine doses that
are still to be licensed. Setting priorities for target popu-
lations to be vaccinated and optimizing resources within
and between countries entails difficult choices. Nonethe-
less, this is critical for a successful global pandemic vac-
cination program, and this needs to be addressed
urgently. The WHO Strategic Advisory Group of Ex-
perts on Immunization (SAGE) Values Framework for
The Allocation and Prioritization of COVID-19 Vaccin-
ation offers core principles for vaccine distribution [5].
These guidelines need to be further specified and tai-
lored to each county, taking into local contexts including
but not limited to the intensity of epidemic, the objec-
tives of pandemic responses, the vaccine supply, and the
size of the population eligible for vaccination.
China was the first country to face the COVID-19
pandemic, although only Wuhan, in Hubei Province,
was hit by a major wave of infections [6]. Nearly the en-
tire population of mainland China (~ 1.4 billion people)
is still susceptible to COVID-19. Recent surges of
COVID-19 cases occurred in a growing number of cities
such as Beijing, Dalian, Urumchi, and Kashgar, following
one or more months without any report of locally ac-
quired infections [7]. There is a risk of a new major wave
of COVID-19, especially after the economy and society
have re-opened both domestically and abroad.
China has invested substantial resources in vaccines
and is one of the main actors in the race to develop a
vaccine to help control the COVID-19 pandemic, with
resources provided by government, manufacturers, and
non-governmental organizations [8]. Eighteen vaccine
candidates are being developed in mainland China; five
of them are in phase III trials as of November 12, 2020
[9]. New COVID-19 vaccine production facilities re-
cently completed or currently under construction are ex-
pected to have the capacity to produce 0.61 billion doses
by the end of 2020 and further expanded in 2021 [10].
However, the output is far behind the quantity needed
to vaccinate a population of nearly 1.4 billion people in
mainland China alone (given a two-dose schedule for all
vaccine candidates).
The Joint Prevention and Control Mechanism of the
State Council roughly divides the target population for
COVID-19 vaccination into three groups, including those
with high risks of exposures to the novel severe acute re-
spiratory syndrome coronavirus 2 (SARS-CoV-2), those
with high-risks of severe outcomes, and the general popu-
lation, with priority given to the former two groups [10].
In July 2020, three COVID-19 vaccines were licensed in
China for emergency use among individuals at high risk of
exposure to SARS-CoV-2, including frontline medical
personnel and overseas workers in China. Media reports
show that over one million people have been vaccinated
as of December 1, 2020 [11, 12]. According to recent sur-
veys [13–15], the (general) Chinese population has a high
level of willingness to accept COVID-19 vaccination.
Hence, with more vaccines expected to be licensed by the
end of 2020/early 2021, there is a need to define the prior-
ity target groups for a wide-scale COVID-19 vaccination
program. This study aims to define the priority target pop-
ulations, their size, and priority for a phased introduction
of COVID-19 vaccination with evolving goals in mainland
China, accounting for risk of severe illness and transmis-
sion. This approach is generalizable to inform national
and regional strategies for the use of COVID-19 vaccines,
especially in low- and middle-income countries.
Methods
Goals of the COVID-19 vaccination program
Using the Pandemic Severity Assessment Framework [16],
developed by the United States (US) Centers for Disease
Control and Prevention to determine pandemic influenza
severity, the COVID-19 pandemic can be characterized as
having both very high transmissibility and clinical severity
[17]. The overarching goal of a vaccination program in the
midst of such a pandemic is to vaccinate all persons will-
ing to be vaccinated. However, due to limited supplies,
prioritization is warranted. The specific goal of COVID-19
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vaccination in China could be determined in a phased ap-
proach. In this early phase, the most important objective
(primary goal) of the vaccination program is to maintain
essential services (e.g., healthcare and national security)
[18, 19]. The second objective (secondary goal) is to re-
duce the number of individuals with severe outcomes, in-
cluding hospitalizations, critical care admissions, and
deaths [18, 19]. In later stages, the objective of the vaccin-
ation program can be further extended to reduce symp-
tomatic infections and/or to stop virus transmission
(tertiary goal). These goals should be adapted along with
the evolving dynamic of the epidemic and an increase of
vaccine supplies. We accordingly refer to this approach as
a phased universal vaccination program.
Priority population groups for a COVID-19 vaccination
program
In line with the aforementioned goals of a COVID-19 vac-
cination program, prioritization is based on utilitarian (i.e.,
maximizing health and economic benefit) and egalitarian
(i.e., protecting the worst off) principles. We define popula-
tion groups to be prioritized by occupation, age, and under-
lying conditions, taking account (1) the interim framework for
COVID-19 vaccine allocation and available guidance on allo-
cating vaccines during an influenza pandemic [e.g. from the
WHO, US and the United Kingdom (UK), see summary in
Additional file 1: Table S1 [5, 18, 20]], (2) the objectives of and
experience gained from the 2009 H1N1 pandemic vaccination
program in China [21], (3) specific high-risk groups for severe
COVID-19 outcomes and high-risk groups for exposures, and
(4) lessons learned from the response to the COVID-19 out-
break in Wuhan such as the role of critical workers in sustain-
ing essential societal functions [1] (Fig. 1). Priority groups
include (1) essential workers, including but not limited to
healthcare workers (utilitarian principles); (2) high-risk individ-
uals such as those at the highest risk of severe/fatal outcomes
(egalitarian principles); (3) individuals who play a key role in





Population Rational for priorityGoal Vaccination tier
Healthcare workers
(n = 10.7 million)
Staff in hospitals, primary healthcare institutions, and public health organizations
(n = 4.7 million)
Justice and law enforcement workers, and armed forces
Law enforcement and security personnel
Personnel in nursing home and social welfare institutions
(n = 0.4 million)
Community workers
(n = 4.5 million)
Staff responsible for the administration of public affairs at the level of village
Staff at sectors of energy, food and transportation
(n = 27.3 million)
Energy denotes the production and supply of electricity, heat, gas and water; food denotes 
food production, agriculture and sideline products processing as well as retail; transportation 
denotes railways, highways, waterways, and air routes 
Those studying/working abroad


























Utilitarian principles: priority given to those
who are most useful
Essential to maintaining effective
functioning of healthcare systems
Egalitarian principles: priority given to the
medically neediest
High risk of occupational exposure
Utilitarian principles: priority given to those
who are most useful
Maintain society functions and national
security; and implement public health
measures during pandemic
Utilitarian principles: priority given to those
who are most useful
Provide care for older adults and the
disabled in institutional settings where 
COVID-19 outbreaks are more likely to 
occur
Utilitarian principles: priority given to those
who are most useful
Utilitarian principles: priority given to those
who are most useful
Assist in the community-level pandemic 
response
Maintain production, processing,
distribution and sales of essential supplies
for people
Have to go to other countries with intense
transmission of SARS-CoV-2 for study/
work
Both utilitarian and egalitarian principles:
priority given to the medically neediest, and


















Older adults ≥ 60 yrs with underlying conditions
(n = 159.2 million)
Older adults ≥ 80 yrs without underlying conditions
(n = 4.4 million)
Older adults aged 60-79 yrs without underlying conditions
(n = 86.2 million)
Individuals <60 yrs with underlying conditions
(n = 309.6 million)
Pregnant women 
(n = 25.6 million)
Highest risk of severe/fatal COVID-19
Highest risk of severe/fatal COVID-19
Egalitarian principles: priority given to the 
medically neediest
Egalitarian principles: priority given to the 
medically neediest
Egalitarian principles: priority given to the 
medically neediest
Possible adverse pregnancy outcome, and





















goal Adults aged 20-59 yrs without underlying conditions
(n = 576.4 million)
School-age children
(n = 190.2 million)
Younger children ≤ 5 yrs
(n = 98.7 million)
Utilitarian principles: priority given to those
who are most useful
Both utilitarian and egalitarian principles:
priority given to primary spreader
Both utilitarian and egalitarian principles:
priority given to primary spreader
Egalitarian principles: priority given to the
most helpless
Contribute more to maintenance of societal
functions and economic well-being; and
provide most care for children
Higher risk of acquiring COVID-19 illness
because of their greater number of contacts
Highest contacts with others, and thus may
become the main spreader of virus if school 
reopens
Priority to the most helpless is based in part 
on the principle of compensatory justice
Fig. 1 Prioritized segments of the population for a COVID-19 vaccination program as well as estimated population size
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Generally, within the populations of interest for the primary
and tertiary vaccination goals, the target population groups
that met ≥ 2 of the aforementioned principles were assigned
to a higher tier. For the secondary goal, the target population
at higher risk of severe/fatal COVID-19 outcome was assigned
to a higher tier. Subsequently, these population groups were
categorized into six vaccination tiers in order of de-
creasing priority. Across priority population groups,
vaccines can be allocated and administered according
to tier, which means that all groups within a tier have
equal priority for vaccination.
Essential workers
Individuals who are critical for preserving essential soci-
etal functions for public health and safety as well as the
well-being of the community during a pandemic include
(1) first responders who may have close contact with po-
tential COVID-19 patients in professional settings, in-
cluding healthcare, public health, and community
workers (these include staff in community service agen-
cies, who maintain supply of daily essential needs for
people under lockdown, and take routine prevention
measures such as fever screening and environmental dis-
infection); (2) individuals who are essential for maintain-
ing national security, namely individuals working in law
enforcement agencies and security personnel (police and
military); (3) workers maintaining production and supply
of daily essentials, including energy, water, food, and
transportation.
Healthcare workers are essential in maintaining an ef-
fective healthcare system, not only for COVID-19 but
also for other healthcare needs. They often have a high
risk of infection due to occupational exposure. For in-
stance, healthcare workers performing endotracheal in-
tubation had a higher risk of SARS-CoV-2 infection than
other healthcare workers (odds ratio 4.33, 95% confi-
dence interval 1.16–16.07) since they had higher expos-
ure associated with aerosol-generating procedures [23].
Public health staff also play a crucial role in the COVID-
19 response, with responsibilities including, but not lim-
ited to, case detection, isolation, tracing, and testing of
close contacts, surveillance, and health communication.
An additional category of essential workers includes
staff in nursing homes and social welfare institutions,
who provide care for older adults and disabled persons
in institutional settings, where COVID-19 outbreaks
could be devastating [24]. Police are necessary for the
society to function and in China are also responsible for
implementing a set of public health measures such as
tracing of cases and close contacts, and isolation. In
addition to maintaining national security, the military
also plays a key role in COVID-19 response, as they can
provide medical care and support the implementation of
prevention and control strategies. Further, community
network members are needed to assist in local pandemic
response such as mass screening and provide support
for vulnerable populations such as seniors, those living
alone, and households complying with voluntary quaran-
tine when a household member is ill. The energy (elec-
tricity, oil, fuel, and natural gas), water, food, and
transportation sectors maintain production, processing,
distribution, and sale of essential supplies for the popu-
lation. These personnel are critical to providing essential
goods and services, and thus need to work even during
periods of community restrictions, social distancing, or
closure orders. Moreover, given the current epidemio-
logical situation in China, characterized by a nearly en-
tirely susceptible population and very limited local
transmission, individuals working or studying abroad
may have a higher risk of exposure to SARS-CoV-2
compared to domestic residents. As such, this class of
individuals has been included in the vaccine emer-
gency programs already implemented in Beijing, Si-
chuan, and Wuhan and is thus included in Tier 2 in
the present study.
Accordingly, we recommend these individuals to be an
appropriate first-level priority target group for vaccin-
ation. We obtained the population size stratified by oc-
cupation from publicly available data, including the
China Economic Census Yearbook 2018, the Tabulation
the 2010 Population Census of the People’s Republic of
China, White Paper on China’s National Defense, Minis-
try of Education, Ministry of Commerce, and published
literature [25–30].
High-risk individuals
To meet the secondary goal of the vaccination program,
individuals who are at increased risk for severe outcome
of COVID-19 could be considered a priority target
population for vaccination. We conducted a narrative lit-
erature review in PubMed, Embase, Web of Science,
medRxiv, and bioRxiv for systematic reviews written in
English, to identify the risk factors of severe illness asso-
ciated with COVID-19. We searched for (“severe” OR
“severity” OR “critical” OR “hospitaliz*” OR “ICU” OR
“death*” OR “mortality” OR “fatal”) AND (“risk factor*”)
AND (“2019-nCov” OR “COVID-19” OR “COVID 19”
OR “2019 novel coronavirus” OR “coronavirus disease
2019” OR “SARS-CoV-2” OR “SARS CoV 2” OR “severe
acute respiratory syndrome coronavirus 2”).
Clark and colleagues extracted the prevalence of
underlying health conditions from the Global Burden of
Diseases, Risk Factors, and Injuries Study (GBD), and es-
timated the number of people with at least one of these
conditions in 2019 for 188 countries [31]. Using Clark’s
method, we updated the probability of having at least
one of these conditions for China to additionally include
the prevalence of body mass index ≥ 30, which were
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identified as risk factors by our review. Then we esti-
mated the age-specific population size of individuals
with any of these conditions by multiplying the esti-
mated probability by the United Nations (UN) mid-year
population estimates for 2020 for China [32]. The popu-
lation size of individuals without these conditions was
calculated subtracting those with health conditions from
the total population.
Pregnant women were additionally included in the list
of high-risk groups. We estimated the number of women
who are pregnant in 1 year as the sum of all live births,
still births, fetal deaths, and abortions in that year. The
number of live births was obtained from China Health
Statistical Yearbook in 2020 [33]. The number of still
births and fetal deaths was estimated as the product of
the number of perinatal deaths and the fraction of those
deaths which are still births and fetus deaths (68.59%)
[34]. We estimated the number of abortions by dividing
the number of induced abortions by the proportion of
induced abortions (88.54%) [35].
Individuals at high risks of symptomatic COVID-19
infections
A second narrative literature review was conducted to
assess the risk of symptomatic COVID-19 infection,
using the search query, (“2019-nCov” OR “COVID-19”
OR “COVID 19” OR “2019 novel coronavirus” OR “cor-
onavirus disease 2019” OR “SARS-CoV-2” OR “SARS
CoV 2” OR “severe acute respiratory syndrome corona-
virus 2”) AND (“incidence” OR “attack rate” OR “mor-
bidity”) AND (“age profile” OR “age group” OR “age
range” OR “age structure” OR “age composition” OR
“age spectrum”). Based on the identified risk factors for
symptomatic COVID-19 infections, we defined the tar-
get populations for vaccination that would help meet the
tertiary goal of reducing illness. The populations size
was obtained from UN mid-year population estimates
for 2020 for China [32], and Ministry of Education of
China [36].
Estimating size of target population of the phased
universal vaccination program
First, we estimated the corresponding population size sep-
arately for each target population as mentioned above.
When a person is included in more than one group, she/
he is intended to be vaccinated in the highest tier group in
which she/he is included. Accordingly, we then excluded
people in more than one risk group to estimate the total
population size stratified by goals of vaccination in differ-
ent phases of the pandemic, and by vaccination tiers.
Assuming vaccine efficacy (VE) around 85–90%, as
preliminary analyses of phase 3 clinical trials of several
COVID-19 vaccines seem to suggest [37], and consider-
ing the basic reproduction number (R0) = 2.5, as found
in previous studies about China [38], we used the well-
known eq. (1 − 1/R0)/VE to estimate the minimum frac-
tion of population to be immunized to reach herd im-
munity [39]. The resulting estimate of the vaccination
coverage is around 70%, in agreement with previous
studies [40]. As a sensitive analysis, we considered more
conservative estimates of vaccine efficacy (around 65–
70%) and thus a vaccination coverage of 90%. Those two
scenarios align well with estimates of willingness to be
vaccinated against COVID-19 in the Chinese population,
namely 72.5–91.3% according to three surveys [13–15].
We therefore estimated the days needed to vaccinate
70% of the targeted population in the sequence of tiers
given a two-dose vaccination schedule, without account-
ing for issues in production capacity (see schematic dia-
gram in Additional file 1: Fig. S1).
During the 2009 influenza pandemic, a maximum of 3
million daily doses of pandemic influenza H1N1
(H1N1pdm) vaccines were administered in China [41].
However, the willingness to be vaccinated against
COVID-19 is higher than that for the 2009 H1N1 pan-
demic [13, 42]. Moreover, the vaccine distribution cap-
acity is likely to be improved as well, spurred by the
progressive enhancement of the roll-out of Supplemen-
tary Immunization Activities in Children in the last dec-
ade [43]. As such, we assumed that the capacity of
COVID-19 vaccination services could be scaled up to 10
million doses administered per day in the baseline ana-
lysis. Sensitivity analyses on the daily doses administered
(3 and 20 million) were conducted as well. We also con-
ducted a sensitivity analysis using an uptake rate of 90%.
Results
Figure 1 illustrates the priority population groups and
the corresponding population size estimated without ex-
cluding duplicates between groups.
Essential workers
It is important to stress that the vaccine may be in
extremely short supply when first available. To meet the
primary goal of vaccination, thus it could be necessary
to consider healthcare workers as the top priority (Tier
1 of the vaccination strategy) based on utilitarian and
egalitarian principles. Law enforcement and security
workers, personnel in nursing home and social welfare
institutes, community workers, workers in energy, food,
and transportation sectors are included in Tier 2 based
on utilitarian principles. Those studying/working abroad
are also included in Tier 2 based on utilitarian and egali-
tarian principles (Fig. 1). We estimated that in mainland
China there are 10.7 million healthcare workers, 4.7 mil-
lion people working in law enforcement agencies and se-
curity personnel, 0.4 million personnel in nursing home
and social welfare institutes, 4.5 million community
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workers, 27.3 million workers in the energy, food, and
transportation sectors, and 2.2 million persons studying/
working abroad.
High-risk individuals
Over 50 published systematic reviews reported the pooled
risk of severe outcome of COVID-19 (Additional file 1:
Table S2). These reviews showed that an increased risk of
severe outcomes from SARS-CoV-2 infection was ob-
served in individuals with chronic respiratory disease,
heart disease, cardio-cerebrovascular disease, hyperten-
sion, diabetes, chronic renal diseases, chronic liver disease,
cancer, and obesity [44–51] (Additional file 1: Table S2).
One systematic review evaluated the disease severity of
COVID-19 during pregnancy and found that 21% were se-
vere/critical cases [52]. COVID-19 may cause fetal dis-
tress, miscarriage, respiratory distress, and preterm
delivery, although evidence for these associations is still
inconclusive [53]. Moreover, pregnant women have high
frequency of antenatal care visits and thus have a possibly
higher exposure to SARS-CoV-2. Although no systematic
review found a significantly higher risk of severe outcomes
for those with immunodeficiency/immunosuppression,
chronic neurological disorders, and sickle cell disorders,
we included these categories in our analysis as recom-
mended by the US and UK [47, 54–56].
Age is one of the most important risk factors for severe/
fatal COVID-19. Our systematic reviews showed that indi-
viduals age≥ 60 years had about 4-fold higher risk of severe/
fatal COVID-19 than younger people (Additional file 1:
Table S2). Wu et al. found that the case-fatality risk for those
aged ≥ 80 years was 1.7–3.6 times that among those aged
70–79 and 60–69 years [57]. Age and underlying conditions
combine to increase the risk [58]. Accordingly, adults ≥ 60
years of age with underlying conditions, and adults ≥ 80 years
of age without underlying conditions, who are at the highest
risk of severe/fatal COVID-19, were considered in Tier 3,
based on egalitarian principles. Compared to these persons,
the risk of severe/fatal COVID-19 among older adults aged
60–79 years without underlying conditions and individuals <
60 years of age with underlying conditions was lower. These
individuals aged < 60 years with pre-existing medical condi-
tions and pregnant women were included in Tier 4 based on
egalitarian principles (Fig. 1).
We estimated that 309.6 million individuals aged < 60
years and 159.2 million individuals aged ≥ 60 years had
at least one high-risk medical condition in mainland
China. The number of pregnant women was thus esti-
mated at 25.6 million in mainland China (Fig. 1).
Individuals at high risks of symptomatic COVID-19
infections
Population-based studies demonstrated that the inci-
dence of COVID-19 cases in those aged 20–59 years was
similar to that among older adults [6, 59] (Additional file
1: Table S4). Our meta-analysis showed the cumulative
incidence was 139–161 per 100,000 persons among
those aged 20–59 years, which was comparable to inci-
dence in those aged ≥ 60 years (195 per 100,000 persons)
(Additional file 1: Fig. S2). These working-age adults had
a higher risk of acquiring COVID-19 symptomatic infec-
tion possibly because of their large number of contacts
at work and in the community [60]. Additionally, they
contribute to maintenance of societal functions and eco-
nomic well-being; and they generally provide care for
children. Given these considerations, individuals aged
20–59 years without underlying conditions (n = 576.4
million) were included in Tier 5 based on both utilitar-
ian and egalitarian principles (Fig. 1).
Population-based sero-epidemiological studies also re-
ported lower seroprevalence in children than in adults [61,
62]. Whether this reflects lower susceptibility of children
to infection in general, or similar infection rates, but much
higher proportions with asymptomatic disease, or rather
the effect of school closures, the implemented strict social
distancing measures, or a self-protective behavior of the
population remains unclear. Modeling studies found con-
flicting results about the effect of interventions targeted at
children on SARS-CoV-2 transmission at the community
level [63, 64], suggesting that there is still uncertainty
surrounding fundamental epidemiological features of
COVID-19 (e.g., children’s infectiousness [65, 66], suscep-
tibility to infection [64, 67], and probability of developing
symptoms) [68]. To ensure the continuity of educational
activities, and reduce transmission, school-age children
(n = 190.2 million) are recommended for vaccination in
Tier 6 based on both utilitarian and egalitarian principles
(Fig. 1).
The incidence of COVID-19 was lower in younger
children. However, the severity among young children
has not been fully addressed. Verdoni et al. reported an
outbreak of a novel severe Kawasaki-like disease in chil-
dren related to COVID-19 in Italy, which raised con-
cerns about the impact of the pandemic on younger
children [69]. Considering such possible post-infectious
inflammatory syndrome as Kawasaki-like disease, youn-
ger children aged ≤ 5 years (n = 98.7 million), which are
priority groups for influenza vaccination, are recom-
mended in Tier 6 as well, based on egalitarian principles
of prioritizing the most vulnerable individuals (Fig. 1).
Estimated size of target population of the phased
universal vaccination program
To maintain essential societal functions, the target popu-
lation of vaccination was estimated at 49.7 million (Tiers
1 and 2, Fig. 1 and Fig. 2). An additional 563.6 million
persons were included in the target population if the
goal of vaccination was extended to reduce the number
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of severe COVID-19 cases (Tiers 3 and 4, Fig. 1 and
Fig. 2). Along with the increase of vaccine supply, the
remaining 784.8 million persons could be further tar-
geted for vaccination to reduce the total number of
COVID-19 symptomatic cases and potentially halt trans-
mission (Tiers 5 and 6, Fig. 1 and Fig. 2). In terms of
vaccination tiers (from Tier 1 to Tier 6), a total of 10.7,
39.0, 162.9, 400.6, 524.1, and 260.7 million persons were
included in the target population (Figs. 1, 3 and 4).
Given 10 million doses administered per day, and a
two-dose vaccination schedule, it will likely take about 7
months to vaccinate 70% of the overall population. How-
ever, only 1 week would be required to vaccinate indi-
viduals working in critical infrastructure sectors (Tier 1
and 2), three weeks for Tier 3, two months for Tier 4,
about 2 months for Tier 5, and 1 month for Tier 6
(Fig. 4, and Additional file 1: Fig. S1). With an expected
0.61 billion doses produced this year [10], and given a
fixed 70% uptake rate among tiers, the estimated vaccine
supply could cover individuals in Tiers 1–3 and half of
individuals in Tier 4 given a two-dose vaccination
schedule.
Sensitivity analyses show it will take 8 months to vaccin-
ate 90% of individuals given 10 million doses administered
each day; 1.8 years to vaccinate 70% of individuals given 3
million doses administered each day; 2.3 years to vaccinate
90% of individuals given 3 million doses administered each
day (Additional file 1: Figs. S3-S5). It will take around
4 months to vaccinate 90% and 70% of individuals respect-
ively, if the capacity of COVID-19 vaccination delivery
was scaled up to 20 million doses administered each day
(Additional file 1: Figs. S6-S7).
Discussion
In the absence of specific antiviral treatment for
COVID-19, vaccination likely represents the most prom-
ising way to control the COVID-19 pandemic. However,
even if a COVID-19 vaccine becomes available, initial
supplies will inevitably be limited. Supply issues could
persist in the long term, due to huge global demand and
limited production capacity. Almost everyone can po-
tentially benefit from vaccination because of residual
high susceptibility to SARS-CoV-2 infection. Consid-
ering different goals of a future vaccination program,
changes in vaccine supplies, various levels of responsi-
bility of population groups to the COVID-19 pan-
demic responses and essential services, as well as the
risk of severe outcome and illness, we recommend a
phased universal COVID-19 vaccination program for
mainland China. Workers in critical sectors, including
healthcare workers, law enforcement and security
personnel, personnel in nursing home, and social wel-
fare institutes, as well as sectors of energy, water,
food, and transportation, and overseas workers/stu-
dents (49.7 million) are the main candidates to re-
ceive high priority for vaccination, in order to
maintain essential societal functions. Subsequently, we
propose to extend the vaccination program to older
adults, pregnant women, and those with underlying
medical conditions (563.6 million), in order to reduce
severe outcomes of COVID-19. Finally, working-age
adults, school-age children, and younger children
(784.8 million) could be vaccinated in order to reduce
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Fig. 2 Estimated size of target population for the COVID-19 vaccination program by goal. a Overlap of target population groups. b Estimated
number of targeted individuals excluding the overlaps between groups. Note that m denotes million
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Target population groups are further grouped into
vaccination tiers from 1 to 6, with Tier 1 having the
highest priority. Even though individuals within a tier
have equal priority for vaccination, it may be necessary
to sub-prioritize vaccination of groups within a tier if
initial vaccine supplies are severely limited. For instance,
cold-chain workers who have been particularly affected
by COVID-19 and are often linked to workplace trans-
mission could thus be vaccinated before other personnel
within Tier 2 [70]. Other examples are represented by
individuals aged ≥ 80 years or older with underlying con-
ditions, who may be vaccinated before other personnel
within Tier 3 or by individuals of < 60 years of age with
≥ 2 underlying conditions who may represent a sub-
prioritized category within their Tier [20]. Further stud-
ies are warranted to examine the sub-prioritization
within each vaccination tier. Although other factors like
smoking, being male, and being an ethnic minority were
found to be risk factors of severe outcome and deaths
from COVID-19 in previous studies [71–73], they were
not accounted for when determining priority population
here due to consideration of equity and feasibility of
vaccination.
The Joint Committee on Vaccination and Immunisa-
tion (JCVI) in the UK largely prioritizes individuals for
vaccination based on age, considering simple age-based
programs to be easier to implement and thus have a
higher chance of achieving a high vaccine uptake [74].
As of December 1, 2020, JCVI does not provide precise
advice on the prioritization for frontline healthcare and
social workers. On the other hand, the Framework for
Equitable Allocation of COVID-19 Vaccine of the Na-
tional Academy of Sciences, Engineering, and Medicine
suggests that in the US priority should be given to front-
line healthcare workers, and those having significant risk
of severe illness or death from COVID-19 (as individuals
with two or more underlying health conditions) [20].
Compared to the UK and the US, the epidemiological
situation in China is quite different, with an almost en-
tirely susceptible population to SARS-CoV-2 infection
and very limited local transmission. In this context, the
frontline workers and individuals studying/working
abroad represent the categories at higher risk of infec-
tions in mainland China. Our advice on priority popula-
tions for a COVID-19 vaccination came under the
umbrella of the WHO SAGE Values Framework for The
5
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Fig. 3 Estimated size of target population for the COVID-19 vaccination program by population group. a Number of individuals. b Proportion.
Note that the overlaps between groups were excluded
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Allocation and Prioritization of COVID-19 Vaccination
[5], and took into consideration the local context and
the possible goals of a COVID-19 vaccination program
in China.
The majority of the current COVID-19 vaccine candi-
dates are being trialed as two-dose schedules [9]. A total
of 70 million, 789 million, and 1099 million doses are
separately needed to cover 70% of individuals in critical
infrastructure sectors, persons at high risk of severe out-
comes of COVID-19, and persons at high risk of acquir-
ing symptomatic illness/infections. Between 2007 and
2015, the volume of all vaccines supplied (n = 55) li-
censed in mainland China varied from 666 million doses
to 1.19 billion doses per year [75]. Several manufacturers
state that a total of 0.61 billion doses of COVID-19 vac-
cine could be produced this year and 2.1 billion doses in
2021 [10]. Even if these candidate vaccines could be li-
censed and manufactured smoothly, it will take 7
months to vaccinate 70% of the general population. This
is assuming an optimistic vaccine delivery rate that is
over twofold higher than the maximum rate at which
H1N1pdm vaccines were delivered in 2009 (3 million
doses administered each day). Such a large-scale vaccin-
ation program like COVID-19 could also represent a
major challenge for current the National Immunization
Program in China, which is currently focused on child-
hood vaccination rather than on adult vaccination. The
limited production capacity will likely further delay
COVID-19 vaccination programs. This dilemma is likely
not unique to China, and other countries across the
world, particularly in low- and middle-income regions,
will face a similar challenge.
Although according to survey results [13–15], 72.5–
91.3% of the Chinese population aged 18 years or above
appear to be willing to accept a COVID-19 vaccine, spe-
cific groups like pregnant women may be less willing to
get COVID-19 vaccine due to safety concerns. These
factors may delay or reduce the effective vaccine cover-
age. The acceptance of COVID-19 vaccination in specific
segments of the population merit further studies.
Identifying individuals with underlying conditions is
critical for a risk-based vaccination campaign. In China,
the National Basic Public Health Service Program pro-
vides all residents with electronic health records, which
have information on underlying conditions and can be
queried by community healthcare centers [76]. Elec-
tronic health records as well as other medical records
may be used to identify high-risk individuals with under-
lying conditions.
Our study has a number of limitations. First, we have
qualitatively discussed the segments of the population to
be prioritized in a COVID-19 vaccination program as
well as the rationale behind prioritization choices. How-
ever, we could not quantitatively examine whether pri-
oritizing older adults to reduce severe outcomes is a
better choice than prioritizing working-age adults or
1 4 36 106 164 203
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Fig. 4 Days needed to vaccinate 70% of the target population, stratified by vaccination tier, under the assumption that 10 million doses are administered per
day. Note that values reported within the square (e.g., 182.5m) denote 70% of the population size in each tier; m denotes million
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school-age children to reduce illness/transmission.
Mathematical modeling is urgently needed to assess
both the health and economic impacts of potential vac-
cination strategies, and the potential to reduce for herd
immunity benefits. Second, we did not consider eligibil-
ity for vaccination due to lack of efficacy and/or safety
concerns that may affect specific groups such as older
adults, people with pre-existing medical conditions,
pregnant women, and very young children, since no vac-
cine has been licensed yet. Third, we did not consider
real-time reactive outbreak immunization strategies be-
cause it is impossible to estimate the corresponding tar-
get population size. However, we strongly recommend
use of COVID-19 vaccination during local outbreaks
coupled with other non-pharmaceutical interventions in
order to prevent subsequent waves of disease. Moreover,
we did not discuss prioritization based on geography;
the risk of COVID-19 exposure may be low in re-
gions that have seen widespread COVID-19 activity
by the time the vaccine is available and have a high
level of population immunity. This may not be par-
ticularly relevant for China where the epidemic has
been well controlled, but it may affect vaccine
prioritization in other regions.
Because of the high burden and limited capacity for
vaccine production, we have highlighted that more at-
tention should be paid to low- and middle-income
countries. The WHO SAGE Values Framework for The
Allocation and Prioritization of COVID-19 Vaccination
offers guidance for allocating and targeting COVID-19
pandemic vaccines, by providing six core principles and
twelve objectives that further specify the six principles
[5]. We tailored it to China-specific contexts account-
ing for the risk of illness and transmission, lessons
learned from the response to the COVID-19 outbreak
in Wuhan, the objectives of COVID-19 pandemic re-
sponses, and experience gained from the 2009 H1N1
pandemic vaccination program in China, in addition to
the risk of severe outcomes, symptomatic illness, and
transmission. Our recommendations for mainland
China could be used as a template for usage of such
guidelines. When a vaccine becomes available, our
recommendations need to be reassessed to consider the
eligibility of population subgroups based on the licen-
sure label. They also need to be further reassessed peri-
odically to account for changes in vaccine supply,
demand, and local epidemiology. Although we propose
a general framework to define vaccination priorities,
the proposed vaccination program needs to be tailored
locally, accounting for country-specific contexts such
the objectives of the pandemic responses, the local level
of transmission, the make-up of first responders, and
essential workers as well as the capacity of
immunization services.
Conclusions
Vaccine deployment is likely to become vitally important
for the global response to the COVID-19 pandemic.
Here we provide a general framework to define priority
groups for a phased introduction of a universal COVID-
19 vaccination program. We applied this framework to
mainland China and further estimated the corresponding
target population sizes. The proposed vaccination pro-
gram could assist Chinese policy-makers in the roll-out
of a large-scale immunization program and be used as a
reference for other countries, especially in low- and
middle-income regions.
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